Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AKRO Stock Forecast 2026-2027
$54.65
Current Price
$4.50B
Market Cap
Buy 1
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to AKRO Price Targets
+6.1%
To High Target of $58.00
+4.3%
To Median Target of $57.00
-1.2%
To Low Target of $54.00
AKRO Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-1.7%
1 Year Change
0.0%
Year-to-Date Change
-6.4%
From 52W High of $58.40
+156.1%
From 52W Low of $21.34
📊 TOP ANALYST CALLS
Did AKRO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Akero is one of their latest high-conviction picks.
Latest AKRO Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, AKRO has a neutral consensus with a median price target of $57.00 (ranging from $54.00 to $58.00). The overall analyst rating is Buy (6.7/10). Currently trading at $54.65, the median forecast implies a 4.3% upside. This outlook is supported by 1 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Nash at Canaccord Genuity, projecting a 6.1% upside. Conversely, the most conservative target is provided by Andrew S. Fein at HC Wainwright & Co., suggesting a 1.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AKRO Analyst Ratings
1
Buy
5
Hold
0
Sell
AKRO Price Target Range
Low
$54.00
Average
$57.00
High
$58.00
Current: $54.65
Latest AKRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AKRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 10, 2025 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $N/A |
| Oct 10, 2025 | HC Wainwright & Co. | Andrew S. Fein | Neutral | Downgrade | $54.00 |
| Oct 9, 2025 | Canaccord Genuity | Edward Nash | Hold | Downgrade | $54.00 |
| Oct 9, 2025 | Jefferies | Andrew Tsai | Hold | Downgrade | $56.00 |
| Sep 4, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Assumes | $72.00 |
| Aug 4, 2025 | TD Cowen | Ritu Baral | Buy | Initiates | $76.00 |
| May 27, 2025 | B of A Securities | Alexandria Hammond | Buy | Maintains | $64.00 |
| May 13, 2025 | Citigroup | Jonathan Woo | Buy | Maintains | $78.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $75.00 |
| Jan 31, 2025 | UBS | Eliana Merle | Buy | Maintains | $109.00 |
| Jan 30, 2025 | B of A Securities | Alexandria Hammond | Buy | Upgrade | $63.00 |
| Jan 28, 2025 | Citigroup | Jonathan Woo | Buy | Maintains | $80.00 |
| Jan 28, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $96.00 |
| Jan 28, 2025 | Canaccord Genuity | Edward Nash | Buy | Maintains | $73.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $72.00 |
| Jan 16, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Nov 18, 2024 | Citigroup | Jonathan Woo | Buy | Initiates | $65.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
Akero Therapeutics, Inc. (AKRO) Competitors
The following stocks are similar to Akero based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Akero Therapeutics, Inc. (AKRO) Financial Data
Akero Therapeutics, Inc. has a market capitalization of $4.50B with a P/E ratio of -14.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -34.5%.
Valuation Metrics
Market Cap
$4.50B
Enterprise Value
$3.76B
P/E Ratio
-14.6x
PEG Ratio
2.6x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+16.4%
Current Ratio
15.8x
Debt/Equity
0.1x
ROE
-34.5%
ROA
-22.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Akero Therapeutics, Inc. (AKRO) Business Model
About Akero Therapeutics, Inc.
What They Do
Develops therapies for metabolic diseases.
Business Model
Akero Therapeutics focuses on developing innovative therapies for serious metabolic diseases, primarily through its lead program involving efruxifermin, an engineered FGF21 analog. The company generates potential revenue by advancing its clinical trials, particularly with promising results from Phase 2b studies and ongoing Phase 3 evaluations that aim to address significant unmet medical needs in metabolic dysfunction-associated steatohepatitis.
Additional Information
The company has demonstrated statistically significant improvements in liver disease conditions and is strategically positioned to be a leader in the biopharmaceutical landscape addressing metabolic liver diseases. Akero's advancements are closely monitored by healthcare stakeholders due to the high prevalence and burden of these conditions, which affects multiple healthcare domains including endocrinology and cardiometabolic care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
74
CEO
Dr. Andrew Cheng M.D., Ph.D.
Country
United States
IPO Year
2019
Website
akerotx.comAkero Therapeutics, Inc. (AKRO) Latest News & Analysis
Latest News
Quick Summary
Novo Nordisk has completed its acquisition of Akero Therapeutics for $54 per share, totaling $4.7 billion, including a Contingent Value Right (CVR).
Why It Matters
Novo Nordisk's acquisition of Akero for $4.7 billion signals strategic expansion into new therapeutic areas, potentially enhancing growth and market position, impacting stock valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Akero Therapeutics is set to be sold to Novo Nordisk for $54.00 per share, plus a potential $6.00 per share contingent payment, as confirmed by legal investigations.
Why It Matters
The investigation into Akero's sale may impact share value and investor confidence, potentially affecting stock performance during the acquisition process.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Akero Therapeutics is under investigation for potential breaches of fiduciary duties and federal securities law violations, as advised by Berger Montague to its shareholders.
Why It Matters
An investigation into Akero Therapeutics for potential fiduciary breaches could signal governance issues, potentially impacting stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Efruxifermin shows antifibrotic effects and potential to reduce disease progression in compensated cirrhosis (F4c) from MASH, supported by analyses from the 96-week Phase 2b SYMMETRY trial.
Why It Matters
Positive data on efruxifermin's antifibrotic effects and its potential to reduce disease progression in compensated cirrhosis could enhance biotech stock values and attract investment interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
My Top 3 Pharma Stocks
7 months ago
Quick Summary
Pharma stocks are underappreciated despite consistent earnings beats and high dividend yields, surpassing those of IT and oil sectors. Three top Big Pharma players are highlighted.
Why It Matters
Rising health issues boost demand for pharmaceutical solutions, while strong earnings and dividends make pharma stocks attractive compared to tech and energy sectors, presenting potential investment opportunities.
Source: Seeking Alpha
Market Sentiment:
Positive
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
8 months ago
Quick Summary
Monteverde & Associates is investigating Akero Therapeutics (NASDAQ: AKRO) following its sale to Novo Nordisk, which offers $54/share and a potential $6/share contingent on regulatory approval.
Why It Matters
The investigation into Akero Therapeutics' sale highlights potential risks for shareholders, including the fairness of the $54.00 per share offer and future regulatory uncertainties.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AKRO Stock
What is Akero Therapeutics, Inc.'s (AKRO) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Akero Therapeutics, Inc. (AKRO) has a median price target of $57.00. The highest price target is $58.00 and the lowest is $54.00.
Is AKRO stock a good investment in 2026?
According to current analyst ratings, AKRO has 1 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $54.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AKRO stock?
Wall Street analysts predict AKRO stock could reach $57.00 in the next 12 months. This represents a 4.3% increase from the current price of $54.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Akero Therapeutics, Inc.'s business model?
Akero Therapeutics focuses on developing innovative therapies for serious metabolic diseases, primarily through its lead program involving efruxifermin, an engineered FGF21 analog. The company generates potential revenue by advancing its clinical trials, particularly with promising results from Phase 2b studies and ongoing Phase 3 evaluations that aim to address significant unmet medical needs in metabolic dysfunction-associated steatohepatitis.
What is the highest forecasted price for AKRO Akero Therapeutics, Inc.?
The highest price target for AKRO is $58.00 from Edward Nash at Canaccord Genuity, which represents a 6.1% increase from the current price of $54.65.
What is the lowest forecasted price for AKRO Akero Therapeutics, Inc.?
The lowest price target for AKRO is $54.00 from Andrew S. Fein at HC Wainwright & Co., which represents a -1.2% decrease from the current price of $54.65.
What is the overall AKRO consensus from analysts for Akero Therapeutics, Inc.?
The overall analyst consensus for AKRO is neutral. Out of 16 Wall Street analysts, 1 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $57.00.
How accurate are AKRO stock price projections?
Stock price projections, including those for Akero Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 4:37 AM UTC